Literature DB >> 17587186

RNA interference of ecto-5'-nucleotidase (CD73) inhibits human breast cancer cell growth and invasion.

Xiuling Zhi1, Sifeng Chen, Ping Zhou, Zhimin Shao, Li Wang, Zhouluo Ou, Lianhua Yin.   

Abstract

Metastasis is a leading cause of mortality and morbidity in breast cancer. Recently, dramatic overexpression of ecto-5'-nucleotidase (CD73), a glycosylphosphatidylinositol-anchored cell surface protein has been found in estrogen receptor-negative [ER (-)] breast cancer cell lines and in clinical samples. In this study, CD73 small interfering RNA (siRNA) plasmid was constructed and stably transfected into breast cancer cell MB-MDA-231 to determine the role of CD73 in breast cancer metastasis and the possible mechanism. Our study demonstrates that CD73 siRNA effectively inhibits CD73 gene expression at mRNA and protein level in MB-MDA-231 cells, leading to in vivo and in vitro growth suppression, prevention of adhesion to extracellular matrix (ECM), and inhibition of invasion and migration. These properties correlate with inhibition of matrix metalloproteinase (MMP)-2 and MMP-9 expression and activity as well as reduction of epidermal growth factor receptor (EGFR) expression. Demonstration of the role of CD73 in breast cancer may lead to new targeted therapies for breast cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17587186     DOI: 10.1007/s10585-007-9081-y

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  31 in total

1.  Role of estrogen receptor in the regulation of ecto-5'-nucleotidase and adenosine in breast cancer.

Authors:  Jozef Spychala; Eduardo Lazarowski; Anna Ostapkowicz; Lanier H Ayscue; Aiwen Jin; Beverly S Mitchell
Journal:  Clin Cancer Res       Date:  2004-01-15       Impact factor: 12.531

2.  Ecto-5'-nucleotidase from a human colon adenocarcinoma cell line. Correlation between enzyme activity and levels in intact cells.

Authors:  J M Navarro; N Olmo; J Turnay; M T López-Conejo; M A Lizarbe
Journal:  Mol Cell Biochem       Date:  1998-10       Impact factor: 3.396

3.  Adenosine receptor mediates motility in human melanoma cells.

Authors:  E C Woodhouse; D F Amanatullah; J A Schetz; L A Liotta; M L Stracke; T Clair
Journal:  Biochem Biophys Res Commun       Date:  1998-05-29       Impact factor: 3.575

4.  RNA interference targeting of A1 receptor-overexpressing breast carcinoma cells leads to diminished rates of cell proliferation and induction of apoptosis.

Authors:  Asra Mirza; Andrea Basso; Stuart Black; Michael Malkowski; Lia Kwee; Jonathan A Pachter; Jean E Lachowicz; Yan Wang; Suxing Liu
Journal:  Cancer Biol Ther       Date:  2005-12-21       Impact factor: 4.742

5.  Lipid rafts remodeling in estrogen receptor-negative breast cancer is reversed by histone deacetylase inhibitor.

Authors:  Anna Ostapkowicz; Kunihiro Inai; Leia Smith; Silvia Kreda; Jozef Spychala
Journal:  Mol Cancer Ther       Date:  2006-02       Impact factor: 6.261

6.  Adenosine-induced apoptosis in EL-4 thymoma cells is caspase-independent and mediated through a non-classical adenosine receptor.

Authors:  Asile El-Darahali; Helen Fawcett; Jamie S Mader; David M Conrad; David W Hoskin
Journal:  Exp Mol Pathol       Date:  2005-09-15       Impact factor: 3.362

7.  Adenosine stimulation of proliferation of breast carcinoma cell lines: evaluation of the [3H]thymidine assay system and modulatory effects of the cellular microenvironment in vitro.

Authors:  Michelle Mujoomdar; Amy Bennett; David Hoskin; Jonathan Blay
Journal:  J Cell Physiol       Date:  2004-12       Impact factor: 6.384

8.  Expression of matrix metalloproteinases in the microenvironment of spontaneous and experimental melanoma metastases reflects the requirements for tumor formation.

Authors:  Uta B Hofmann; Andreas A O Eggert; Katharina Blass; Eva-B Bröcker; Jürgen C Becker
Journal:  Cancer Res       Date:  2003-12-01       Impact factor: 12.701

9.  Neutrophil adherence to endothelium is enhanced via adenosine A1 receptors and inhibited via adenosine A2 receptors.

Authors:  B N Cronstein; R I Levin; M Philips; R Hirschhorn; S B Abramson; G Weissmann
Journal:  J Immunol       Date:  1992-04-01       Impact factor: 5.422

10.  CD73 is involved in lymphocyte binding to the endothelium: characterization of lymphocyte-vascular adhesion protein 2 identifies it as CD73.

Authors:  L Airas; J Hellman; M Salmi; P Bono; T Puurunen; D J Smith; S Jalkanen
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307

View more
  63 in total

1.  Selective activation of anti-CD73 mechanisms in control of primary tumors and metastases.

Authors:  Dipti Vijayan; Deborah S Barkauskas; Kimberley Stannard; Erin Sult; Rebecca Buonpane; Kazuyoshi Takeda; Michele W L Teng; Kris Sachsenmeier; Carl Hay; Mark J Smyth
Journal:  Oncoimmunology       Date:  2017-04-05       Impact factor: 8.110

2.  CD73 Promotes Glioblastoma Pathogenesis and Enhances Its Chemoresistance via A2B Adenosine Receptor Signaling.

Authors:  Angela Yan; Michelle L Joachims; Linda F Thompson; Andrew D Miller; Peter D Canoll; Margaret S Bynoe
Journal:  J Neurosci       Date:  2019-03-29       Impact factor: 6.167

3.  Anti-CD73 in cancer immunotherapy: awakening new opportunities.

Authors:  Luca Antonioli; Gennady G Yegutkin; Pál Pacher; Corrado Blandizzi; György Haskó
Journal:  Trends Cancer       Date:  2016-02-01

4.  Upregulation of CD73 Confers Acquired Radioresistance and is Required for Maintaining Irradiation-selected Pancreatic Cancer Cells in a Mesenchymal State.

Authors:  Anna M Nguyen; Jianhong Zhou; Brihget Sicairos; Sangeetha Sonney; Yuchun Du
Journal:  Mol Cell Proteomics       Date:  2019-12-26       Impact factor: 5.911

5.  Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis.

Authors:  John Stagg; Upulie Divisekera; Nicole McLaughlin; Janelle Sharkey; Sandra Pommey; Delphine Denoyer; Karen M Dwyer; Mark J Smyth
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-04       Impact factor: 11.205

6.  SnoRNA U50 is a candidate tumor-suppressor gene at 6q14.3 with a mutation associated with clinically significant prostate cancer.

Authors:  Xue-Yuan Dong; Carmen Rodriguez; Peng Guo; Xiaodong Sun; Jeffrey T Talbot; Wei Zhou; John Petros; Qunna Li; Robert L Vessella; Adam S Kibel; Victoria L Stevens; Eugenia E Calle; Jin-Tang Dong
Journal:  Hum Mol Genet       Date:  2008-01-17       Impact factor: 6.150

7.  NTPDase3 and ecto-5'-nucleotidase/CD73 are differentially expressed during mouse bladder cancer progression.

Authors:  Liliana Rockenbach; Elizandra Braganhol; Fabrícia Dietrich; Fabrício Figueiró; Manoella Pugliese; Maria Isabel Albano Edelweiss; Fernanda Bueno Morrone; Jean Sévigny; Ana Maria Oliveira Battastini
Journal:  Purinergic Signal       Date:  2014-01-26       Impact factor: 3.765

Review 8.  Membrane microparticles: shedding new light into cancer cell communication.

Authors:  Paloma Silva de Souza; Roberta Soares Faccion; Paula Sabbo Bernardo; Raquel Ciuvalschi Maia
Journal:  J Cancer Res Clin Oncol       Date:  2015-08-19       Impact factor: 4.553

9.  The proliferation, apoptosis, invasion of endothelial-like epithelial ovarian cancer cells induced by hypoxia.

Authors:  Pengfei Zhu; Yanxia Ning; Liangqing Yao; Mo Chen; Congjian Xu
Journal:  J Exp Clin Cancer Res       Date:  2010-09-10

10.  Downregulation of CD73 in 4T1 breast cancer cells through siRNA-loaded chitosan-lactate nanoparticles.

Authors:  Farhad Jadidi-Niaragh; Fatemeh Atyabi; Ali Rastegari; Esmail Mollarazi; Melika Kiani; Alireza Razavi; Mehdi Yousefi; Nasim Kheshtchin; Hadi Hassannia; Jamshid Hadjati; Fazel Shokri
Journal:  Tumour Biol       Date:  2016-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.